GET DAILY SIGNALSFaeth Therapeutics (FTH): Analyst Targets Signal +168% Upside to $59
Key Takeaways
- The central target used here is $59, the arithmetic mean of eight verified, current analyst price targets, rounded to the nearest dollar.
- With shares near $22.05, reaching $59 would require an upside of roughly 168% — a very large move.
- Reviewed targets ranged from about $55 to $69, reflecting broad agreement on direction but meaningful disagreement on magnitude.
- The strongest support comes from FTH's lead asset PIKTOR and an upcoming year-end Phase 2 readout in advanced endometrial cancer.
- The biggest risks are clinical-trial failure, a binary data outcome, and the heavy cash burn typical of a clinical-stage biotech.
- For more context on the company, you can explore its Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- For broader market ideas, you can also explore Trending AI Robots to see what AI-driven strategies are currently highlighting.
Analyst Price Targets and Consensus View
Faeth Therapeutics, Inc. (FTH) is a clinical-stage oncology biotech formerly known as Sensei Biotherapeutics, renamed in June 2026. Its most recent widely reported earnings (the quarter ending June 30, 2026) showed a GAAP net loss of about $16.0 million, consistent with a company that has no product revenue yet. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Because FTH is a development-stage company, analyst valuation relies on probability-weighted views of its pipeline rather than current earnings. The eight most recent, attributable price targets reviewed here were: Guggenheim ($69, revised from $70), H.C. Wainwright ($60), Oppenheimer ($60), Lucid Capital ($59), Baird ($57), Needham ($56), BTIG ($55), and JonesTrading ($55). Their arithmetic mean rounds to $59, with a range of roughly $55 to $69.
The overall posture is uniformly bullish — every firm cited carries a Buy or equivalent rating — but the spread reflects genuine uncertainty. Analysts model different probabilities of success for PIKTOR in endometrial versus breast cancer and different peak-sales assumptions. Guggenheim, for example, has cited a potential peak annual sales figure of about $1.5 billion by 2035 for PIKTOR under a favorable scenario, while lower targets embed more conservative timelines. The $59 figure is a calculated average, not an official published consensus, and no analyst target is a guarantee.
Current Market Position and Path Toward the Target
At a recent price near $22.05, FTH carries a market capitalization of roughly $570 million and sits well below its 52-week high of about $42.14, though far above its 52-week low near $7.45. Reaching $59 implies a gain of about 168%, which is a very large move for any stock and is especially dependent on clinical news rather than quarterly fundamentals.
The likely path hinges on binary catalysts. FTH's lead program, PIKTOR — an oral combination of serabelisib and sapanisertib targeting the PI3K/AKT/mTOR pathway — is being studied in second-line advanced endometrial cancer (the PIK-201 study) and in HR+/HER2- advanced breast cancer. Positive year-end Phase 2 topline data could trigger a substantial repricing toward the higher end of the target range; disappointing data could compress the stock sharply. There is no established revenue stream to cushion a negative readout.
What Could Support a Move Toward the Target
- Pipeline optionality: PIKTOR addresses the PI3K/AKT/mTOR pathway across two tumor types, and FTH also has Solnerstotug, a VISTA-targeting antibody, plus earlier-stage assets.
- Unmet need: Analysts including Guggenheim cite an underserved market in HR+ metastatic breast cancer and durable-response differentiation for PIKTOR.
- Bullish analyst positioning: Multiple firms initiated coverage with Buy ratings in 2026, and several reiterated targets into the fourth quarter.
- Cash and risk-reward: Lucid Capital has described current levels as offering attractive risk-reward into the year-end readout.
What Could Prevent the Target From Being Reached
- Clinical failure: A negative or ambiguous Phase 2 result would likely remove the core thesis underpinning higher targets.
- Rising competition: The bar in oncology is shifting toward durability of response and survival benefit, not response rate alone, as antibody-drug conjugates advance.
- Cash burn: As a pre-revenue biotech, FTH may need additional financing, which can dilute shareholders and pressure valuation.
- Binary volatility: Small sample sizes in early cohorts mean modest changes in responder counts can swing statistical confidence — and the stock price — dramatically.
Technical Levels and Market Structure
FTH has shown high volatility, ranging from about $7.45 to $42.14 over the past year. The $30 area marks a prior trading zone from earlier in 2026, and the $42 level represents the 52-week high and a notable overhead resistance level. On the downside, the low-$20s and the $7.45 low define the broader support structure. These levels matter because a data-driven breakout above resistance, or a breakdown on negative news, could define the next leg for the stock.
Time Horizon and What Investors Should Monitor
Analyst price targets are typically framed around a 12-month research horizon, though specific horizons vary by firm and are not always disclosed. For FTH, the single most important near-term event is the expected year-end Phase 2 topline readout for PIKTOR in second-line advanced endometrial cancer, with initial breast-cancer data anticipated the following year. Investors should also monitor cash runway and any financing announcements, analyst target revisions around data events, and broader biotech sector sentiment, which can amplify moves in clinical-stage names. From what I see, this is important because the binary nature of the catalyst leaves little room for error.
Final Assessment
Can FTH reach $59? The figure represents a calculated average of eight current analyst price targets spanning roughly $55 to $69, implying a very large move of about 168% from a price near $22.05. The thesis rests almost entirely on PIKTOR's clinical success, with a year-end Phase 2 readout in endometrial cancer as the decisive catalyst. Positive data could validate the higher end of the range; failure would make even the lower targets difficult to justify. The wide target spread underscores genuine disagreement about clinical probability, not just valuation. Investors should weigh the binary risk carefully and watch the upcoming data, cash position, and any analyst revisions.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like FTH, traders can use these signals to discover opportunities, monitor positions, and spot changing trends more efficiently than manual screening alone. I find this helpful when reviewing names with upcoming binary events, as it adds another layer to my own review process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FTH's Stochastic Oscillator reaches overbought zone
The Stochastic Oscillator for FTH moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for FTH entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FTH's RSI Oscillator exited the oversold zone, 24 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on FTH as a result. In 71 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for FTH just turned positive on October 29, 2026. Looking at past instances where FTH's MACD turned positive, the stock continued to rise in 42 of 47 cases over the following month. The odds of a continued upward trend are 89%.
Following a +3.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTH advanced for three days, in 169 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
FTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. FTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.294) is normal, around the industry mean (3.498). P/E Ratio (-0.362) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement